Caspofungin for lung diseases, interstitial

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Mar 2025: Trial registered, NCT06892951
  2. 2 Dec 2025: Trial started, NCT06892951

The trials

NCT06892951: CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

State
Under way
Phase
Phase 1 and Phase 2
People
100 planned
Started
2 Dec 2025
Primary completion
Dec 2026
Arms
Part 2 - randomized study (group 1), Part 1 - open study
Results
None posted
  1. 25 Mar 2025: Trial registered
  2. 2 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Caspofungin Acetate 50 MG.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.